Novo Nordisk A/S - Share Repurchase Programme

Published: Oct 02, 2017

Bagsværd, Denmark, 2 October 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 16 billion to be executed during a 12-month period beginning 2 February 2017.

Under the programme initiated 9 August 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 3.9 billion in the period from 9 August 2017 to 30 October 2017.

Since the announcement as of 25 September 2017, the following transactions have been made under the programme:

Number of
B shares
Average
purchase price
Transaction
value, DKK
Accumulated, last announcement 7,499,590 2,205,950,196
25 September 2017 210,000 308.05 64,691,388
26 September 2017 220,000 303.69 66,812,522
27 September 2017 210,000 302.86 63,600,266
28 September 2017 215,000 303.85 65,328,427
29 September 2017 215,000 301.53 64,829,174
Accumulated under the programme 8,569,590 2,531,211,974

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 41,621,013 B shares of DKK 0.20, corresponding to 1.7% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,500,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 16 billion during a 12-month period beginning 2 February 2017. As of 29 September 2017, Novo Nordisk has repurchased a total of 40,517,561 B shares equal to a transaction value of DKK 10,831,183,966.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

Further information

Media:
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Christina Kjær +45 3079 3009 cnje@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

Company announcement No 75 / 2017

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/e441384b-27ce-4465-8966-3f277ba16f31

Back to news